President Donald Trump signed an executive order on April 18 to expand access to psychedelic drugs as treatments for Americans with mental health disorders.
The order directed federal agencies to accelerate the process of research and approval for psychedelics, including ibogaine, a plant-derived compound currently classified as a Schedule I substance.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.